Cancer Pharmacology Core
The Cancer Pharmacology Core provides DF/HCC investigators with the necessary expertise and resources to design and undertake pharmacokinetic studies in the context of phase I and phase II clinical trials, and preclinical investigations. The core has the ability to implement and validate previously developed analytical methods to quantify drugs and their metabolites in biological fluids as well as the capability to modify or develop entirely new assays when warranted. The core also offers comprehensive analysis of pharmacokinetic data as an additional service, including the estimation of pharmacokinetic parameters and identifying their relationship to pathophysiological variables and pharmacodynamic effects.
Leadership and Staff
Research Associate: Xiaoying He, PhD
Olga Tretyakov, MD
PUBLICATION ACKNOWLEDGEMENT: If research supported by this core facility results in publication, please acknowledge this support by including the following in your publication(s):
We thank Dana-Farber/Harvard Cancer Center in Boston, MA, for the use of the Cancer Pharmacology Core, which provided __________ service. Dana-Farber/Harvard Cancer Center is supported in part by a NCI Cancer Center Support Grant # NIH 5 P30 CA06516.